Mico BioMed Co. Ltd. Total Liabilities

Latest as of September 2025: ₩7.88 Billion KRW ≈ $5.34 Million USD

Mico BioMed Co. Ltd. total liabilities. Based on the latest financial reports, Mico BioMed Co. Ltd. (214610) has total liabilities worth ₩7.88 Billion KRW (≈ $5.34 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Mico BioMed Co. Ltd. (214610) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Mico BioMed Co. Ltd. (2015–2024)

Total liabilities of Mico BioMed Co. Ltd. from 2015 to 2024. This chart illustrates how Mico BioMed Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data.

Mico BioMed Co. Ltd. Competitors by Total Liabilities

The table below lists competitors of Mico BioMed Co. Ltd. ranked by their total liabilities.

Company Country Total Liabilities
Scilex Holding Company
NASDAQ:SCLX
USA $564.05 Million
Nafpaktos Textile Industry S.A
AT:NAYP
Greece €18.91 Million
Imexhs Ltd
AU:IME
Australia AU$8.36 Million
INOVIQ LTD.
F:EGQ0
Germany €1.72 Million
Wintao Communications Co. Ltd
SHE:301139
China CN¥1.42 Billion
Little Green Pharma Ltd
AU:LGP
Australia AU$11.59 Million
MONY Group plc
LSE:MONY
UK GBX152.90 Million
Prajay Engineers Syndicate Limited
NSE:PRAENG
India Rs3.29 Billion

Liability Composition Analysis (2015–2024)

This chart breaks down Mico BioMed Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 214610 current and non-current assets.

Liquidity & Leverage Metrics

Mico BioMed Co. Ltd. Total Liabilities Ratios Explained

Mico BioMed Co. Ltd. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 4.88 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.31 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.23 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Mico BioMed Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Mico BioMed Co. Ltd. (2015–2024)

The table below shows the annual total liabilities of Mico BioMed Co. Ltd. from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 ₩28.58 Billion
≈ $19.37 Million
+14.38%
2023-12-31 ₩24.99 Billion
≈ $16.93 Million
-37.24%
2022-12-31 ₩39.82 Billion
≈ $26.98 Million
+9.34%
2021-12-31 ₩36.42 Billion
≈ $24.68 Million
+142.82%
2020-12-31 ₩15.00 Billion
≈ $10.16 Million
-37.53%
2019-12-31 ₩24.01 Billion
≈ $16.27 Million
+30.16%
2018-12-31 ₩18.45 Billion
≈ $12.50 Million
+41.64%
2017-12-31 ₩13.02 Billion
≈ $8.83 Million
+130.32%
2016-12-31 ₩5.65 Billion
≈ $3.83 Million
+0.74%
2015-12-31 ₩5.61 Billion
≈ $3.80 Million
--

About Mico BioMed Co. Ltd.

KQ:214610 Korea Publishing
Market Cap
$13.00 Million
₩19.18 Billion KRW
Market Cap Rank
#26245 Global
#1972 in Korea
Share Price
₩2290.00
Change (1 day)
-2.35%
52-Week Range
₩2255.00 - ₩4615.00
All Time High
₩12100.26
About

RollingStone Co., Ltd. provides point-of-care-testing diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real… Read more